Teksoz, SerapIchedef, Cigdem AcarOzyuncu, SenihaMuftuler, Fazilet Zumrut BiberUnak, PerihanMedine, Ilker EminErtay, TurkanEren, Mine Sencan2019-10-272019-10-2720111084-9785https://doi.org/10.1089/cbr.2010.0854https://hdl.handle.net/11454/45963The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium (Tc-99m) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of Tc-99m-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. Tc-99m-D-PA-Glu exhibited more accumulation on PC-3 cells versus Tc-99m-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of Tc-99m-D-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. Tc-99m-D-PA-Glu and Tc-99m-D-PA have exhibited different biodistribution results.en10.1089/cbr.2010.0854info:eu-repo/semantics/closedAccessglucuronidationPC-3 cell linepenicillamineradiolabelingscintigraphyTc-99mArticle265623630WOS:00029608730001221950558Q2